Rallybio Corp (NASDAQ: RLYB)’s stock price has plunge by -9.20relation to previous closing price of 1.74. Nevertheless, the company has seen a -10.23% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-12 that RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.
Is It Worth Investing in Rallybio Corp (NASDAQ: RLYB) Right Now?
RLYB has 36-month beta value of -1.59. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RLYB is 17.24M, and currently, short sellers hold a 7.60% ratio of that float. The average trading volume of RLYB on April 25, 2024 was 1.61M shares.
RLYB’s Market Performance
RLYB’s stock has seen a -10.23% decrease for the week, with a 5.33% rise in the past month and a 13.67% gain in the past quarter. The volatility ratio for the week is 10.30%, and the volatility levels for the past 30 days are at 11.96% for Rallybio Corp The simple moving average for the past 20 days is -11.61% for RLYB’s stock, with a -51.21% simple moving average for the past 200 days.
Analysts’ Opinion of RLYB
Many brokerage firms have already submitted their reports for RLYB stocks, with Jefferies repeating the rating for RLYB by listing it as a “Hold.” The predicted price for RLYB in the upcoming period, according to Jefferies is $1.50 based on the research report published on February 07, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see RLYB reach a price target of $18. The rating they have provided for RLYB stocks is “Buy” according to the report published on April 17th, 2023.
Wedbush gave a rating of “Outperform” to RLYB, setting the target price at $17 in the report published on April 10th of the previous year.
RLYB Trading at -12.41% from the 50-Day Moving Average
After a stumble in the market that brought RLYB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.71% of loss for the given period.
Volatility was left at 11.96%, however, over the last 30 days, the volatility rate increased by 10.30%, as shares surge +7.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.82% lower at present.
During the last 5 trading sessions, RLYB fell by -10.23%, which changed the moving average for the period of 200-days by -70.19% in comparison to the 20-day moving average, which settled at $1.7930. In addition, Rallybio Corp saw -33.89% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RLYB
The total capital return value is set at -0.74. Equity return is now at value -54.13, with -50.37 for asset returns.
Based on Rallybio Corp (RLYB), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -153.74. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 47.61.
Currently, EBITDA for the company is -78.78 million with net debt to EBITDA at 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.39.
Conclusion
To put it simply, Rallybio Corp (RLYB) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
